All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

312

Reset

312 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • TQB3617Phase 21 trial

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Myelofibrosis

  • TT-01488Phase 21 trial

    TransThera Sciences (Nanjing), Inc. · Mantle Cell Lymphoma (MCL)

  • TuspetinibHM43239Phase 21 trial

    Aptose Biosciences Inc. · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML

  • U16Phase 21 trial

    Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · Relapsed or Refractory Non-Hodgkin's Lymphoma

  • UCART20x22Phase 21 trial

    Cellectis S.A. · B-cell Non-Hodgkin Lymphoma (B-NHL)

  • UCART22Phase 21 trial

    Cellectis S.A. · B-cell Acute Lymphoblastic Leukemia

  • Vebeglogene autotemcelBeta-globin lentiviral vector transduced autologous HSPCsPhase 21 trial

    Lantu Biopharma · Beta-Thalassemia

  • VI-0609Phase 21 trial

    VIVUS LLC · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma

  • VTRU200Phase 21 trial

    Vitruviae · Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome

  • WTX-330Phase 21 trial

    Werewolf Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma

  • YKST02Phase 21 trial

    Excyte Biopharma Ltd · Relapsed or Refractory Multiple Myeloma (RRMM)

  • zevor-celCAR-BCMA T CellPhase 21 trial

    CARsgen Therapeutics Co., Ltd. · Multiple Myeloma

NewerPage 7 of 7

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.